Deutsch Intern
Department of General Practice

ABS ambulant

Development of the S3 Guideline “Recommendations for an Outpatient Antibiotic Stewardship Program for Germany"

Context

The majority of antibiotic prescriptions in Germany are issued in outpatient care. At the same time, a substantial proportion of these prescriptions are avoidable or not in line with guideline recommendations. In everyday practice, general practitioners as well as pediatricians face the challenge of using antibiotics for infectious diseases in a targeted, appropriate, and resistance-conscious manner. To date, there is no cross-indication S3 guideline on Antibiotic Stewardship (ABS) for the outpatient setting.

 

Project Objective

The aim of the project is to develop a new S3 guideline to support the responsible and evidence-based use of antibiotics in outpatient primary care for adults and children. As a first step, clinically relevant key questions and patient-relevant outcomes will be prioritized through an interdisciplinary process. This will be followed by a systematic evidence search and appraisal (including GRADE methodology). On this basis, consensus-based recommendations for an outpatient Antibiotic Stewardship Program in Germany will be developed. In addition, a full-length version, a short version, and a patient guideline are planned. A particular focus is placed on feasibility within the German healthcare system and on the involvement of relevant stakeholders in medical self-governance and routine care delivery.

 

Project Partners

Consortium Lead:
Institute of General Practice, University Hospital Würzburg

Consortium Partners:

  • Institute of General Practice, Kiel University
  • Institute of General Practice, Jena University Hospital
  • University of Bremen

Cooperation Partners (selection):

  • German College of General Practitioners and Family Physicians (DEGAM)
  • German Society for General Outpatient Pediatrics (DGAAP)
  • German Society for Pediatric Infectious Diseases (DGPI)
  • German Society for Infectious Diseases (DGI), ABS Section
  • German Association of Office-Based Physicians for Infectious Diseases and HIV Medicine (DAGNÄ)
  • German Society for Hygiene and Microbiology (DGHM)
  • German Society of Public Health (DGÖG)
  • Robert Koch Institute (RKI)
  • Drug Commission of German Pharmacists (AMK) and Drug Commission of the German Medical Association
  • German Association of General Practitioners and Family Physicians
  • Professional Association of Pediatricians (BVKJ)
  • National Association of Statutory Health Insurance Physicians (KBV)
  • Citizen and practice representatives (including BayFoNet, RESPoNsE)

 

Funding

Public funding of approximately EUR 392,000 from the G-BA Innovation Fund is available for the guideline project. The planned funding period is 30 months. The project is registered with the Association of the Scientific Medical Societies in Germany (AWMF) as a new S3 guideline (Registry No. 053-066).